Gritstone Bio Inc is a biotechnology company focused on developing personalized cancer immunotherapies that harness the body's immune system to target and eradicate tumors
The company aims to create innovative treatments tailored to individual patients by utilizing unique tumor-specific neoantigens, which are proteins produced by cancer cells. By leveraging advanced genomic and computational technologies, Gritstone Bio works to enhance the efficacy of immunotherapy, providing hope for improved outcomes in cancer care and addressing significant unmet medical needs within the oncology field.
Gritstone bio, Inc. (Nasdaq: GRTS) (“Gritstone” or the “Company”), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced it has filed a voluntary petition under chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.
Gritstone Bio's Phase 2 data for GRANITE in MSS-CRC shows promising results, including a 38% risk reduction for patients with low ctDNA. Gritstone plans to review the data with the FDA for potential next steps.
--Encouraging progression-free survival data in overall population; continued follow-up needed to allow data to mature further, especially in low ctDNA subgroup where events accrue more slowly
-- Preliminary randomized Phase 2 data suggest GRANITE (personalized neoantigen vaccine) could drive meaningful clinical benefit in front-line metastatic microsatellite-stable colorectal cancer (MSS-CRC); mature progression-free survival (PFS) data expected in the third quarter of 2024 --
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Gritstone bio, Inc. (NASDAQ: GRTS) on behalf of long-term stockholders following a class action complaint that was filed against Gritstone on June 7, 2024 with a Class Period from March 9, 2023 to February 29, 2024. Our investigation concerns whether the board of directors of Gritstone have breached their fiduciary duties to the company.
